- Home
- JAZZ vs IEX Comparison
JAZZ vs IEX Comparison
Compare JAZZ & IEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | IEX |
|---|---|---|
| Founded | 2003 | 1987 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 15.4B |
| IPO Year | 2007 | 1994 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | IEX |
|---|---|---|
| Price | $247.13 | $236.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $217.57 | ★ $229.63 |
| AVG Volume (30 Days) | 702.7K | ★ 703.9K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.31% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.17 | 3.54 |
| Revenue | $1,618,693,000.00 | ★ $3,457,500,000.00 |
| Revenue This Year | $6.22 | $4.09 |
| Revenue Next Year | $7.68 | $4.36 |
| P/E Ratio | ★ $35.67 | $65.94 |
| Revenue Growth | N/A | ★ 5.77 |
| 52 Week Low | $112.53 | $158.19 |
| 52 Week High | $265.05 | $243.80 |
Technical Indicators
Market Signals| Indicator | JAZZ | IEX |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 63.39 |
| Support Level | $222.49 | $216.54 |
| Resistance Level | $250.49 | $243.80 |
| Average True Range (ATR) | 7.19 | 5.83 |
| MACD | -0.96 | 0.56 |
| Stochastic Oscillator | 15.93 | 70.81 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About IEX IDEX Corporation
Idex manufactures pumps, flow meters, valves, and fluidic systems for customers in a variety of end markets, including industrial, fire and safety, life science, and water. The firm's business is organized into three segments: fluid and metering technologies, health and science technologies, and fire and safety and diversified products. The company generated $3.5 billion in revenue in 2025.